Multiple Dose Study of UCB4940 in Subjects With Psoriatic Arthritis

Summary

A study of UCB4940 in subjects with psoriatic arthritis to evaluate the safety and body distribution of UCB4940 in those patients. Neither the patient nor the doctor will know the treatment group.

Timeline

Start

2014-05

Primary completion

2015-08

Completion

2015-08

Outcome

Met primary endpoint

paper The PoC trial met both prespecified efficacy success criteria and showed rapid, profound responses in both joint and skin PMID 29275332 ↗

Publications

• Glatt S, Baeten D, Baker T, Griffiths M, Ionescu L, Lawson ADG, Maroof A, Oliver R, Popa S, Strimenopoulou F, Vajjah P, Watling MIL, Yeremenko N, Miossec P, Shaw S. Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation. Ann Rheum Dis. 2018 Apr;77(4):523-532. doi: 10.1136/annrheumdis-2017-212127. Epub 2017 Dec 23.

Drugs

Indications